Catherine Jankowski
Concepts (301)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Exercise | 35 | 2024 | 1929 | 5.110 |
Why?
| HIV Infections | 35 | 2024 | 2701 | 3.860 |
Why?
| Frailty | 7 | 2024 | 153 | 2.230 |
Why?
| Body Composition | 15 | 2024 | 644 | 1.680 |
Why?
| Caregivers | 4 | 2024 | 810 | 1.510 |
Why?
| Motivation | 6 | 2024 | 546 | 1.450 |
Why?
| Neoplasms | 7 | 2023 | 2464 | 1.270 |
Why?
| Aging | 12 | 2024 | 1750 | 1.230 |
Why?
| Dehydroepiandrosterone | 3 | 2018 | 51 | 1.230 |
Why?
| Bone Density | 8 | 2021 | 474 | 1.220 |
Why?
| Quality of Life | 11 | 2025 | 2680 | 1.160 |
Why?
| Aged | 41 | 2024 | 21953 | 0.990 |
Why?
| Exercise Therapy | 7 | 2024 | 413 | 0.980 |
Why?
| Integrative Medicine | 1 | 2025 | 11 | 0.950 |
Why?
| Drama | 1 | 2024 | 5 | 0.910 |
Why?
| Muscle, Skeletal | 7 | 2023 | 1627 | 0.900 |
Why?
| Complementary Therapies | 1 | 2025 | 86 | 0.880 |
Why?
| Collagen Type I | 3 | 2021 | 117 | 0.820 |
Why?
| Independent Living | 1 | 2024 | 98 | 0.810 |
Why?
| Alkaline Phosphatase | 2 | 2021 | 142 | 0.790 |
Why?
| Ibuprofen | 2 | 2021 | 80 | 0.790 |
Why?
| Art Therapy | 1 | 2022 | 17 | 0.770 |
Why?
| Muscle Strength | 3 | 2024 | 305 | 0.770 |
Why?
| Middle Aged | 43 | 2024 | 30889 | 0.720 |
Why?
| Health Education | 1 | 2024 | 333 | 0.720 |
Why?
| Poverty | 1 | 2024 | 496 | 0.710 |
Why?
| Lipopolysaccharide Receptors | 1 | 2021 | 88 | 0.700 |
Why?
| Humans | 80 | 2025 | 128418 | 0.680 |
Why?
| Interleukin-6 | 2 | 2021 | 716 | 0.680 |
Why?
| HIV Long-Term Survivors | 1 | 2020 | 3 | 0.680 |
Why?
| Mitochondria, Muscle | 1 | 2021 | 110 | 0.680 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2021 | 336 | 0.660 |
Why?
| Critical Illness | 1 | 2025 | 730 | 0.630 |
Why?
| Interleukin-10 | 1 | 2021 | 299 | 0.630 |
Why?
| Attitude to Health | 2 | 2019 | 431 | 0.610 |
Why?
| Wearable Electronic Devices | 1 | 2019 | 43 | 0.610 |
Why?
| Risk Reduction Behavior | 1 | 2020 | 209 | 0.590 |
Why?
| Preventive Health Services | 1 | 2020 | 145 | 0.580 |
Why?
| Peptides | 3 | 2021 | 908 | 0.580 |
Why?
| Anti-HIV Agents | 7 | 2020 | 747 | 0.580 |
Why?
| Frail Elderly | 6 | 2024 | 121 | 0.570 |
Why?
| Adiposity | 3 | 2013 | 504 | 0.550 |
Why?
| Female | 52 | 2025 | 68154 | 0.540 |
Why?
| Perception | 1 | 2019 | 338 | 0.520 |
Why?
| Resistance Training | 2 | 2024 | 151 | 0.520 |
Why?
| Adaptation, Physiological | 3 | 2021 | 514 | 0.510 |
Why?
| Male | 41 | 2025 | 62858 | 0.510 |
Why?
| Hormone Replacement Therapy | 3 | 2018 | 89 | 0.490 |
Why?
| Cross-Sectional Studies | 13 | 2024 | 5039 | 0.480 |
Why?
| Dehydroepiandrosterone Sulfate | 3 | 2013 | 46 | 0.470 |
Why?
| Estrogens | 4 | 2013 | 342 | 0.470 |
Why?
| Guidelines as Topic | 2 | 2019 | 260 | 0.470 |
Why?
| Telemedicine | 1 | 2023 | 782 | 0.460 |
Why?
| Fatigue | 5 | 2022 | 317 | 0.450 |
Why?
| Self Efficacy | 4 | 2024 | 374 | 0.430 |
Why?
| Sex Factors | 2 | 2018 | 1945 | 0.420 |
Why?
| Heart Failure | 2 | 2023 | 2145 | 0.420 |
Why?
| Qualitative Research | 6 | 2024 | 1226 | 0.390 |
Why?
| Survivors | 2 | 2014 | 463 | 0.380 |
Why?
| Nausea | 2 | 2023 | 107 | 0.380 |
Why?
| Inflammation | 3 | 2021 | 2654 | 0.370 |
Why?
| Bone and Bones | 2 | 2013 | 299 | 0.350 |
Why?
| Interviews as Topic | 3 | 2024 | 715 | 0.350 |
Why?
| Physical Fitness | 4 | 2017 | 203 | 0.350 |
Why?
| Acetaminophen | 1 | 2012 | 243 | 0.330 |
Why?
| Cardiovascular Diseases | 3 | 2020 | 1999 | 0.320 |
Why?
| Health Status | 2 | 2020 | 755 | 0.320 |
Why?
| Postmenopause | 5 | 2019 | 348 | 0.320 |
Why?
| HIV-1 | 5 | 2020 | 836 | 0.290 |
Why?
| Sarcopenia | 2 | 2023 | 74 | 0.290 |
Why?
| Healthy Aging | 2 | 2024 | 34 | 0.280 |
Why?
| Menopause | 2 | 2021 | 291 | 0.280 |
Why?
| Adolescent | 10 | 2025 | 20179 | 0.270 |
Why?
| Accelerometry | 2 | 2019 | 91 | 0.270 |
Why?
| Pain | 2 | 2023 | 757 | 0.260 |
Why?
| Child, Preschool | 6 | 2025 | 10384 | 0.260 |
Why?
| Glucose | 1 | 2011 | 982 | 0.260 |
Why?
| Motor Activity | 3 | 2014 | 668 | 0.250 |
Why?
| Weight Loss | 4 | 2020 | 725 | 0.240 |
Why?
| Adult | 19 | 2025 | 35300 | 0.240 |
Why?
| Cancer Survivors | 2 | 2021 | 263 | 0.240 |
Why?
| Biomarkers | 6 | 2021 | 3880 | 0.240 |
Why?
| Radioisotope Dilution Technique | 1 | 2004 | 13 | 0.230 |
Why?
| Body Water | 1 | 2004 | 18 | 0.230 |
Why?
| Urine | 1 | 2004 | 54 | 0.230 |
Why?
| Social Stigma | 2 | 2023 | 118 | 0.230 |
Why?
| Missouri | 1 | 2024 | 68 | 0.230 |
Why?
| Serum | 1 | 2004 | 57 | 0.230 |
Why?
| Chile | 1 | 2024 | 20 | 0.220 |
Why?
| Deuterium | 1 | 2004 | 86 | 0.220 |
Why?
| Absorptiometry, Photon | 4 | 2021 | 248 | 0.220 |
Why?
| Contraceptives, Oral, Hormonal | 1 | 2004 | 30 | 0.220 |
Why?
| Feasibility Studies | 2 | 2025 | 860 | 0.220 |
Why?
| Cardiorespiratory Fitness | 2 | 2024 | 49 | 0.220 |
Why?
| Lumbar Vertebrae | 3 | 2018 | 230 | 0.210 |
Why?
| Intention | 1 | 2024 | 162 | 0.210 |
Why?
| Parents | 2 | 2022 | 1304 | 0.210 |
Why?
| Saliva | 1 | 2004 | 207 | 0.210 |
Why?
| Heart Rate | 2 | 2024 | 800 | 0.200 |
Why?
| Aged, 80 and over | 8 | 2021 | 7033 | 0.200 |
Why?
| Proxy | 1 | 2022 | 27 | 0.190 |
Why?
| Child | 7 | 2025 | 20655 | 0.190 |
Why?
| Surveys and Questionnaires | 8 | 2024 | 5362 | 0.190 |
Why?
| High-Intensity Interval Training | 1 | 2022 | 24 | 0.190 |
Why?
| Malnutrition | 1 | 2023 | 79 | 0.190 |
Why?
| Femur | 2 | 2018 | 245 | 0.190 |
Why?
| Voltage-Dependent Anion Channel 1 | 1 | 2021 | 9 | 0.190 |
Why?
| Symptom Assessment | 1 | 2023 | 126 | 0.190 |
Why?
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2021 | 41 | 0.190 |
Why?
| Citrate (si)-Synthase | 1 | 2021 | 58 | 0.190 |
Why?
| Residence Characteristics | 1 | 2024 | 326 | 0.180 |
Why?
| Attitude | 1 | 2023 | 249 | 0.180 |
Why?
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 42 | 0.180 |
Why?
| Prospective Studies | 3 | 2023 | 7036 | 0.180 |
Why?
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2021 | 83 | 0.180 |
Why?
| Raloxifene Hydrochloride | 2 | 2013 | 14 | 0.170 |
Why?
| Advance Directives | 1 | 2021 | 76 | 0.170 |
Why?
| Viral Load | 2 | 2020 | 450 | 0.170 |
Why?
| Protective Factors | 1 | 2020 | 91 | 0.160 |
Why?
| Life Expectancy | 1 | 2020 | 60 | 0.160 |
Why?
| Perimenopause | 1 | 2020 | 60 | 0.160 |
Why?
| Superoxide Dismutase | 1 | 2021 | 326 | 0.160 |
Why?
| Health Behavior | 1 | 2024 | 741 | 0.160 |
Why?
| Cell Phone | 1 | 2020 | 70 | 0.160 |
Why?
| Epigenesis, Genetic | 1 | 2023 | 615 | 0.150 |
Why?
| Placebos | 2 | 2011 | 201 | 0.150 |
Why?
| Disabled Persons | 2 | 2018 | 140 | 0.150 |
Why?
| DNA Methylation | 1 | 2023 | 604 | 0.150 |
Why?
| Blood Glucose | 4 | 2013 | 2093 | 0.150 |
Why?
| Mexican Americans | 1 | 1999 | 113 | 0.150 |
Why?
| Housing | 1 | 2019 | 131 | 0.150 |
Why?
| United States | 4 | 2024 | 13830 | 0.150 |
Why?
| Insulin | 5 | 2013 | 2315 | 0.140 |
Why?
| Chronic Disease | 2 | 2021 | 1705 | 0.140 |
Why?
| Advance Care Planning | 1 | 2021 | 203 | 0.140 |
Why?
| Muscle Proteins | 1 | 2019 | 221 | 0.140 |
Why?
| Sleep Wake Disorders | 1 | 2020 | 250 | 0.140 |
Why?
| Randomized Controlled Trials as Topic | 2 | 2022 | 1356 | 0.130 |
Why?
| Self Care | 1 | 2020 | 368 | 0.130 |
Why?
| Obesity | 3 | 2016 | 2858 | 0.130 |
Why?
| Colorado | 2 | 2024 | 4375 | 0.130 |
Why?
| Women's Health | 1 | 2019 | 362 | 0.130 |
Why?
| Risk Factors | 7 | 2020 | 9704 | 0.130 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2021 | 1185 | 0.130 |
Why?
| Pelvic Bones | 1 | 2018 | 155 | 0.130 |
Why?
| Anxiety | 1 | 2023 | 955 | 0.130 |
Why?
| Physical Therapists | 1 | 2017 | 61 | 0.120 |
Why?
| Estradiol | 1 | 2019 | 486 | 0.120 |
Why?
| Sentinel Lymph Node Biopsy | 1 | 2016 | 108 | 0.120 |
Why?
| Adaptation, Psychological | 2 | 2020 | 616 | 0.120 |
Why?
| Monitoring, Physiologic | 1 | 2016 | 266 | 0.110 |
Why?
| Hospitalization | 1 | 2024 | 2057 | 0.110 |
Why?
| Stress, Psychological | 2 | 2020 | 1060 | 0.110 |
Why?
| Sleep | 1 | 2020 | 676 | 0.110 |
Why?
| Selective Estrogen Receptor Modulators | 1 | 2013 | 26 | 0.110 |
Why?
| Diet, Protein-Restricted | 1 | 2013 | 11 | 0.110 |
Why?
| Decision Making | 1 | 2021 | 847 | 0.110 |
Why?
| Physical Therapy Modalities | 1 | 2017 | 293 | 0.110 |
Why?
| Pyridoxine | 1 | 2013 | 32 | 0.110 |
Why?
| Neoadjuvant Therapy | 1 | 2016 | 381 | 0.110 |
Why?
| Activities of Daily Living | 1 | 2017 | 384 | 0.110 |
Why?
| Gastrointestinal Microbiome | 1 | 2021 | 633 | 0.110 |
Why?
| Treatment Outcome | 3 | 2025 | 10152 | 0.110 |
Why?
| Developmental Disabilities | 1 | 2016 | 257 | 0.110 |
Why?
| Microbiota | 1 | 2021 | 719 | 0.100 |
Why?
| Anti-Retroviral Agents | 1 | 2015 | 230 | 0.100 |
Why?
| Risk Assessment | 2 | 2020 | 3232 | 0.100 |
Why?
| Homocystinuria | 1 | 2013 | 69 | 0.100 |
Why?
| Double-Blind Method | 2 | 2008 | 1848 | 0.100 |
Why?
| Estrogen Replacement Therapy | 1 | 2013 | 137 | 0.100 |
Why?
| Young Adult | 3 | 2025 | 12312 | 0.100 |
Why?
| Thigh | 2 | 2010 | 53 | 0.100 |
Why?
| Urea Cycle Disorders, Inborn | 1 | 2012 | 23 | 0.100 |
Why?
| Depression | 2 | 2019 | 1296 | 0.100 |
Why?
| Public Health | 1 | 2017 | 482 | 0.100 |
Why?
| Hysterectomy | 1 | 2012 | 118 | 0.090 |
Why?
| Marijuana Smoking | 1 | 2015 | 239 | 0.090 |
Why?
| Prognosis | 1 | 2020 | 3772 | 0.090 |
Why?
| Lipids | 2 | 2013 | 620 | 0.090 |
Why?
| Osteoporosis, Postmenopausal | 1 | 2011 | 40 | 0.090 |
Why?
| Sports | 1 | 1994 | 224 | 0.090 |
Why?
| Acquired Immunodeficiency Syndrome | 1 | 2012 | 222 | 0.090 |
Why?
| Osteogenesis | 1 | 2012 | 175 | 0.090 |
Why?
| Cholesterol, HDL | 1 | 2011 | 203 | 0.090 |
Why?
| Hip | 2 | 2011 | 55 | 0.090 |
Why?
| Insulin-Like Growth Factor I | 2 | 2013 | 307 | 0.090 |
Why?
| Accidental Falls | 1 | 2012 | 168 | 0.090 |
Why?
| Osteoporosis | 1 | 2013 | 233 | 0.090 |
Why?
| Subcutaneous Fat | 1 | 2010 | 74 | 0.080 |
Why?
| Intra-Abdominal Fat | 1 | 2010 | 88 | 0.080 |
Why?
| Cholesterol | 1 | 2011 | 406 | 0.080 |
Why?
| Cholesterol, LDL | 1 | 2011 | 360 | 0.080 |
Why?
| Follicle Stimulating Hormone | 2 | 2021 | 235 | 0.080 |
Why?
| Triglycerides | 1 | 2011 | 523 | 0.080 |
Why?
| Cognition Disorders | 1 | 2013 | 497 | 0.080 |
Why?
| Sex Hormone-Binding Globulin | 1 | 2008 | 53 | 0.080 |
Why?
| Geriatric Assessment | 2 | 2023 | 205 | 0.080 |
Why?
| Dyslipidemias | 1 | 2010 | 176 | 0.070 |
Why?
| Case-Control Studies | 2 | 2013 | 3328 | 0.070 |
Why?
| Linear Models | 2 | 2008 | 813 | 0.070 |
Why?
| Area Under Curve | 2 | 2010 | 279 | 0.070 |
Why?
| Weight Gain | 1 | 2011 | 503 | 0.070 |
Why?
| Diet | 2 | 2006 | 1199 | 0.070 |
Why?
| Vascular Stiffness | 1 | 2012 | 464 | 0.070 |
Why?
| Body Mass Index | 3 | 2013 | 2261 | 0.070 |
Why?
| Transcription, Genetic | 1 | 2012 | 1404 | 0.060 |
Why?
| Calcium, Dietary | 1 | 2006 | 56 | 0.060 |
Why?
| Focus Groups | 2 | 2019 | 452 | 0.060 |
Why?
| Cognition | 1 | 2013 | 1107 | 0.060 |
Why?
| Regression Analysis | 1 | 2008 | 978 | 0.060 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 1999 | 2430 | 0.060 |
Why?
| Testosterone | 1 | 2008 | 373 | 0.060 |
Why?
| Energy Metabolism | 3 | 2013 | 831 | 0.060 |
Why?
| Breast Neoplasms | 1 | 2016 | 2132 | 0.060 |
Why?
| Longitudinal Studies | 2 | 2024 | 2710 | 0.050 |
Why?
| Florida | 1 | 2023 | 93 | 0.050 |
Why?
| Rest | 1 | 2004 | 122 | 0.050 |
Why?
| Social Support | 2 | 2018 | 589 | 0.050 |
Why?
| C-Peptide | 1 | 2004 | 163 | 0.050 |
Why?
| Vitamin D | 1 | 2006 | 380 | 0.050 |
Why?
| Glucose Tolerance Test | 1 | 2004 | 356 | 0.050 |
Why?
| Predictive Value of Tests | 1 | 2008 | 1935 | 0.050 |
Why?
| CD4 Lymphocyte Count | 2 | 2013 | 267 | 0.050 |
Why?
| Habits | 1 | 2022 | 43 | 0.050 |
Why?
| Time Factors | 4 | 2019 | 6482 | 0.050 |
Why?
| Insulin Resistance | 1 | 2010 | 1164 | 0.050 |
Why?
| Survival Analysis | 2 | 2015 | 1263 | 0.050 |
Why?
| Sex Characteristics | 1 | 2006 | 721 | 0.050 |
Why?
| Adipose Tissue | 1 | 2005 | 589 | 0.050 |
Why?
| Actigraphy | 1 | 2020 | 94 | 0.040 |
Why?
| Death | 1 | 2021 | 121 | 0.040 |
Why?
| Comorbidity | 1 | 2024 | 1543 | 0.040 |
Why?
| Premenopause | 1 | 2020 | 121 | 0.040 |
Why?
| Family | 1 | 2023 | 651 | 0.040 |
Why?
| Postprandial Period | 1 | 1999 | 103 | 0.040 |
Why?
| Counseling | 1 | 2021 | 382 | 0.040 |
Why?
| Estrogen Receptor alpha | 1 | 2019 | 132 | 0.040 |
Why?
| Research Design | 1 | 2024 | 1036 | 0.040 |
Why?
| Affect | 1 | 2020 | 285 | 0.030 |
Why?
| Health Services for the Aged | 1 | 2017 | 72 | 0.030 |
Why?
| Axilla | 1 | 2016 | 43 | 0.030 |
Why?
| Sentinel Lymph Node | 1 | 2016 | 42 | 0.030 |
Why?
| Disabled Children | 1 | 2016 | 69 | 0.030 |
Why?
| Human Activities | 1 | 2015 | 19 | 0.030 |
Why?
| Liver | 1 | 2004 | 1826 | 0.030 |
Why?
| Professional Role | 1 | 2017 | 160 | 0.030 |
Why?
| Smartphone | 1 | 2016 | 88 | 0.030 |
Why?
| Lymph Node Excision | 1 | 2016 | 165 | 0.030 |
Why?
| Pandemics | 1 | 2023 | 1476 | 0.030 |
Why?
| Tracheostomy | 1 | 2016 | 119 | 0.030 |
Why?
| Body Constitution | 1 | 1994 | 53 | 0.030 |
Why?
| Aging, Premature | 1 | 2013 | 13 | 0.030 |
Why?
| Betaine | 1 | 2013 | 72 | 0.030 |
Why?
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 39 | 0.030 |
Why?
| ADP-ribosyl Cyclase 1 | 1 | 2013 | 37 | 0.030 |
Why?
| Body Fat Distribution | 1 | 2013 | 49 | 0.030 |
Why?
| Homocysteine | 1 | 2013 | 149 | 0.030 |
Why?
| Methionine | 1 | 2013 | 157 | 0.030 |
Why?
| Europe | 1 | 2013 | 359 | 0.030 |
Why?
| Amino Acids, Essential | 1 | 2012 | 13 | 0.020 |
Why?
| Neoplasm Staging | 1 | 2016 | 1290 | 0.020 |
Why?
| Amino Acids, Branched-Chain | 1 | 2012 | 36 | 0.020 |
Why?
| Dietetics | 1 | 2012 | 22 | 0.020 |
Why?
| Nutritional Support | 1 | 2012 | 31 | 0.020 |
Why?
| Muscles | 1 | 2013 | 322 | 0.020 |
Why?
| Respiration, Artificial | 1 | 2016 | 598 | 0.020 |
Why?
| Ovariectomy | 1 | 2012 | 136 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2023 | 3376 | 0.020 |
Why?
| United Kingdom | 1 | 2012 | 257 | 0.020 |
Why?
| Antiretroviral Therapy, Highly Active | 1 | 2013 | 266 | 0.020 |
Why?
| Dietary Proteins | 1 | 2012 | 128 | 0.020 |
Why?
| Bone Remodeling | 1 | 2011 | 71 | 0.020 |
Why?
| Carotid Arteries | 1 | 2012 | 195 | 0.020 |
Why?
| Membrane Glycoproteins | 1 | 2013 | 466 | 0.020 |
Why?
| Enteral Nutrition | 1 | 2012 | 182 | 0.020 |
Why?
| Cohort Studies | 1 | 2020 | 5388 | 0.020 |
Why?
| Weight Reduction Programs | 1 | 2011 | 111 | 0.020 |
Why?
| Gene Expression Regulation | 1 | 2019 | 2505 | 0.020 |
Why?
| Contraceptive Agents | 1 | 2010 | 64 | 0.020 |
Why?
| Oxygen Consumption | 1 | 2012 | 669 | 0.020 |
Why?
| Infant | 2 | 2013 | 8914 | 0.020 |
Why?
| Lymphocyte Activation | 1 | 2013 | 1098 | 0.020 |
Why?
| Mental Health | 1 | 2015 | 686 | 0.020 |
Why?
| Ultrasonography | 1 | 2012 | 710 | 0.020 |
Why?
| Neuropsychological Tests | 1 | 2013 | 1002 | 0.020 |
Why?
| Quality Improvement | 1 | 2017 | 1094 | 0.020 |
Why?
| Executive Function | 1 | 2013 | 422 | 0.020 |
Why?
| Drug Administration Schedule | 1 | 2010 | 751 | 0.020 |
Why?
| Dietary Supplements | 1 | 2012 | 531 | 0.020 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2013 | 846 | 0.020 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2013 | 1046 | 0.020 |
Why?
| Patient Compliance | 1 | 2010 | 560 | 0.020 |
Why?
| Incidence | 1 | 2012 | 2616 | 0.020 |
Why?
| Buttocks | 1 | 2005 | 12 | 0.020 |
Why?
| Antineoplastic Agents | 1 | 2016 | 2051 | 0.010 |
Why?
| Abdomen | 1 | 2005 | 116 | 0.010 |
Why?
| Follow-Up Studies | 1 | 2011 | 4892 | 0.010 |
Why?
| Retrospective Studies | 1 | 2019 | 14454 | 0.010 |
Why?
| Infant, Newborn | 1 | 2012 | 5687 | 0.010 |
Why?
| Tomography, X-Ray Computed | 1 | 2010 | 2523 | 0.010 |
Why?
| Eating | 1 | 1995 | 368 | 0.010 |
Why?
|
|
Jankowski's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|